SOLID-STATE CONFORMATIONS AND ANTIDOPAMINERGIC EFFECTS OF REMOXIPRIDE HYDROCHLORIDE AND A CLOSELY RELATED SALICYLAMIDE, FLA 797, IN RELATION TO DOPAMINE RECEPTOR MODELS
- 1 October 1986
- journal article
- research article
- Vol. 30 (4) , 345-351
Abstract
The X-ray structure of two new 2,6-disubstituted benzamides, i.e., remoxipride hydrochloride monohydrate ((-)-(S)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenzamide hydrochloride monohydrate) and FLA 797 ((-)-(S)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamide), have been determined as well as the distribution coefficients. The difference in dopamine receptor blocking activity is discussed in terms of lipophilicity and solid state conformations of the two benzamides. The major difference between the solid state conformations lies in the orientation of carboxamide moiety. In remoxipride the carbonyl group is oriented almost perpendicularly to the benzene ring, thus preventing the formation of a hydrogen-bonded pseudo-ring between the amide hydrogen and the methoxy group found in other types of o-methoxybenzamides. In FLA 797, however, this pseudo-ring is present in the planar conformation of the salicylamide moiety. This conformation is further stabilized by a hydrogen bond between the phenol group and the carbonyl oxygen. The side chain in remoxipride adopts an extended conformation in contrast to FLA 797, where the side chain has a folded conformation. The crystal structures are related to current topographic dopamine receptor models developed from more rigid antidopaminergic compounds. Based on these comparisons. It is suggested that benzamides having an N-ethyl-2-pyrrolidinylmethyl side chain interact with the receptor in the folded conformation. The binding affinity is thought to be further increased by the planar conformation of the salicylamide moiety present in FLA 797, which permits an efficient .pi.-.pi. stacking interaction.This publication has 8 references indexed in Scilit:
- Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brainEuropean Journal of Pharmacology, 1984
- NMR Conformational Study of Aminoalkylbenzamides, Aminoalkyl‐o‐anisamides, and Metoclopramide, a Dopamine Receptor AntagonistHelvetica Chimica Acta, 1984
- Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activitiesJournal of Medicinal Chemistry, 1982
- Dopamine receptor model and its application in the design of a new class of rigid pyrrolo[2,3-g]isoquinoline antipsychoticsJournal of Medicinal Chemistry, 1981
- SUBSTITUTED BENZAMIDE DRUGS AS SELECTIVE NEUROLEPTIC AGENTS1981
- Mapping the dopamine receptor. 2. Features derived from modifications in the rings A/B region of the neuroleptic butaclamolJournal of Medicinal Chemistry, 1979
- Synthesis and pharmacological properties of a series of antidopaminergic piperidyl benzamidesJournal of Pharmacy and Pharmacology, 1977
- Crystallographic studies on neuroleptics of the benzocycloheptapyridoisoquinoline series. The crystal structure of butaclamol hydrobromide and the absolute configuration and crystal structure of dexclamol hydrobromideCanadian Journal of Chemistry, 1976